J Nanostruct 14(2): 578-587, Spring 2024

REVIEW PAPER

Synergistic Effects of Paclitaxel and Doxorubicin with Liposomes Nanoparticles in Cancer Therapy: A Review

Tadjibaeva Muyassar Karimbaevna [1], Azamov Omadjon Burkhanovich [2], Zokirova Sokhiba [3], Gafur-Akhunov Mirza Ali [4], Yuldasheva Dilnavoz Xasanovna [5], Mirzayunusova Ziyoda Ibragimovna [6], Egamberdiev Salim Karimberdievich [4], Jalilov Olimjon Mukhidinovich [7], Bahrom Shafkarov [8], Jumaniyozova Lola Khudayberganovna [9], Sheraliyeva Munavvar Abdullayevna [10], Sulaymanov Dilshod Abdirakhimovich [11], Mashaev Eldor Ergashvoy ugli [12]*

[1] *Nukus State Pedagogical Institute, Nukus, Uzbekistan*
[2] *Andijan State Institute of Foreign Languages, Uzbekistan*
[3] *Fergana State University , Uzbekistan*
[4] *Department of Oncology, Center for Professional Development of Medical Workers, Tashkent, Uzbekistan*
[5] *Department of Pharmacology of Bukhara State Medical Institute, Bukhara, Uzbekistan*
[6] *Department of Methods of Russian Language and Literature, Kokand State Pedagogical Institute, Kokand, Uzbekistan*
[7] *Department of Foreign Languages in Preschool and Primary Education, Jizzakh State Pedagogical University, Uzbekistan*
[8] *Tashkent Institute of Irrigation and Agricultural Mechanization, Engineers National Research University, Tashkent, Uzbekistan*
[9] *Department of Fruits and Vegetables, Urganch State University, Uzbekistan*
[10] *Department of Pre-School Education Metaphysics, Termez State University of Uzbekistan, , Uzbekistan*
[11] *Department of Urology an Oncology, Fergana medical institute of public health, Fergana, Uzbekistan*
[12] *Department of Chemical Technology of Oil and Gas Refining, Tashkent Institute of Chemical Technology, Tashkent, Uzbekistan*

ARTICLE INFO

Article History:
Received 08 January 2024
Accepted 17 March 2024
Published 01 April 2024

Keywords:
Cancer
Doxorubicin
Liposome Nanoparticle
Nanotechnology
Paclitaxel

ABSTRACT

Cancer treatment often faces challenges related to drug resistance, limited bioavailability, and severe side effects. Nanotechnology has emerged as a promising solution to enhance the efficacy and specificity of chemotherapeutic agents. Combining traditional anticancer drugs like Paclitaxel and Doxorubicin with lipid nanoparticles could potentially overcome these barriers and improve patient outcomes. Paclitaxel and Doxorubicin, when formulated, significantly enhance cancer therapy by improving drug delivery and reducing side effects. Combining these drugs with lipid nanoparticles further boosts their efficacy, ensuring targeted action against cancer cells. This synergistic approach offers a promising pathway towards more effective and less toxic cancer treatments. This review synthesizes recent research findings on the use of Paclitaxel and Doxorubicin with lipid nanoparticles, focusing on their combined therapeutic efficacy, mechanisms of action, and potential advantages over traditional formulations. The aim of this review paper is to explore the synergistic effects of Paclitaxel and Doxorubicin formulations when combined with lipid nanoparticles in cancer therapy. The review highlights that combining Paclitaxel and Doxorubicin with lipid nanoparticles offers significant improvements in targeted drug delivery, bioavailability, and therapeutic outcomes, paving the way for more effective and less toxic cancer treatments.

How to cite this article
Karimbaevna T., Burkhanovich A., Sokhiba Z. et al. Synergistic Efects of Paclitaxel and Doxorubicin with Liposomes Nanoparticles in Cancer Therapy: A Review. J Nanostruct, 2024; 14(2):578-587. DOI:10.22052/JNS.2024.02.019

* *Corresponding Author Email: tadjibaevamuyassarkarimbaevna@outlook.com*

INTRODUCTION

Cancer remains one of the leading causes of mortality worldwide, with conventional remedies regularly restrained with the aid of drug resistance, negative bioavailability, and excessive facet results [1]. A few drugs like Paclitaxel and Doxorubicin have been widely utilized in cancer remedy due to their effectiveness in inhibiting most cancers cellular growth [2]. Current advancements in nanotechnology have introduced lipid nanoparticles as a promising approach to the shipping and efficacy of chemotherapeutic drugs. Lipid nanoparticles can enhance drug solubility, stability, and focused transport, thereby decreasing off-goal results and enhancing healing effects [3]. When Paclitaxel and Doxorubicin are formulated and mixed with lipid nanoparticles, they show off synergistic effects that significantly improve most cancers treatment [4]. The combination of Paclitaxel and Doxorubicin with lipid nanoparticles offers numerous over conventional formulations [5]. Those include more advantageous drug uptake via cancer cells, reduced efflux via MDR transporters, and extended retention of the medication inside the tumor microenvironment [6]. This synergistic approach no longer only improves the healing efficacy but additionally minimizes the unfavorable side results associated with conventional chemotherapy [7]. The goal of this review is to discover the synergistic consequences of Paclitaxel and Doxorubicin formulations whilst combined with lipid nanoparticles in cancer therapy. by way of synthesizing recent research findings, this assessment highlights the potential of this aggregate remedy to overcome the limitations of traditional approaches.

MECHANISMS OF ACTION

Paclitaxel: Mechanism and Efficacy

Paclitaxel, is an outstanding member of the taxane family by $C_{47}H_{51}NO_{14}$ chemical formula (Fig. 1 showed chemical structure of it). The prototype of this class, emerges from a natural source is a chemotherapeutic agent renowned for its efficacy in cancer remedy [8]. It features by means of disrupting the normal dynamics of microtubules, which can be crucial components of the cellule's cytoskeleton concerned in mitosis. in particular, Paclitaxel binds to the beta-tubulin subunits of microtubules, stabilizing them and stopping their DE polymerization [9]. This interference halts the everyday reorganization of the microtubule community required for mitotic spindle formation, effectively arresting the cell cycle on the G2/M segment and triggering apoptosis (programmed cellular dying). This mechanism is vital as it targets swiftly dividing most cancers cells, which might be relatively depending on successful mitotic strategies [10]. Paclitaxel has validated large efficacy throughout quite a number cancer,



Fig. 1. Chemical structure of paclitaxel

together with ovarian, breast, lung, and pancreatic cancers. Its scientific software has been validated via several trials and studies [11]. for instance, in metastatic breast most cancers, the nab-paclitaxel components (nanoparticle albumin-sure paclitaxel) has shown a typical reaction fee (ORR) of 40% and a clinical benefit fee (CBR) of 66%, with a mean development-free survival (PFS) of 7.64 months and median usual survival (OS) of 24.51 months. these consequences underscore the drug's strong healing capability and its pivotal role inside the oncology healing arsenal [12].

To optimize its therapeutic profile, Paclitaxel is available in several superior formulations designed to decorate its delivery and efficacy while minimizing negative consequences. The conventional system, Taxol, utilizes Cremophor EL as a solvent, that's associated with allergic reaction reactions. To mitigate such risks, more recent formulations along with Abraxane (albumin-bound paclitaxel) and Lipusu (liposomal paclitaxel) had been evolved [13]. Abraxane enhances solubility and stability and helps focused delivery, lowering systemic toxicity and enhancing medical effects. further, Lipusu leverages liposomal technology to enhance the pharmacokinetic homes of Paclitaxel, ensuring extended move time and better tumor localization. moreover, innovative transport systems like micelles, polymeric nanoparticles, and stable dispersions are being explored to further beautify bioavailability, targeting accuracy, and overall healing efficacy [14]. According to Taisuke Mori et al, take a look at, Paclitaxel is uncommon in that it accumulates specifically in most cancers cells and induces apoptosis for 1 week in vivo and in vitro. on the other hand, paclitaxel couldn't be detected in cancer tissues after 2 weeks. The administration of paclitaxel on a weekly schedule, rather than the same old every-three-week schedule, may produce greater tumor-cell demise [15]. Based on Jérôme Alexandre et al, study, the accumulation of H_2O_2 is an early and important step for paclitaxel-prompted most cancers cellular dying earlier than the commitment of the cells into apoptosis. these effects suggest that ROS participate in vitro and in vivo to paclitaxel cytotoxicity [16].

Doxorubicin: Mechanism and Efficacy

Doxorubicin, by C_{27} H_{29} NO_{11} chemical formula (Fig. 2 showed chemical structure of it) also recognized as a chemotherapy medication extensively used in the treatment of various cancers, together with breast cancer, bladder most cancers, Kaposi's sarcoma, lymphoma, and acute lymphoblastic leukemia [17]. It belongs to the anthracycline and antitumor antibiotic family of medications. Doxorubicin exerts its anticancer outcomes thru a couple of mechanisms, DNA intercalation, topoisomerase II inhibition, technology of reactive oxygen species (ROS), and histone eviction. DNA intercalation disrupts the DNA shape and inhibits DNA replication and transcription. Topoisomerase II inhibition prevents the enzyme vital for DNA replication and repair, main to DNA strand breaks and cellular dying. ROS generation causes oxidative damage to cell components, including DNA, proteins, and lipids. Histone eviction disrupts the interplay among DNA and histones, further destabilizing the chromatin structure and promoting apoptosis (programmed cell dying) [18]. Doxorubicin is available in diverse formulations to decorate its therapeutic efficacy and decrease aspect consequences, including the free form, liposomal formulations, polymeric micelles, nanoparticles, and polymer-drug conjugates. these superior formulations enhance drug solubility, balance, and focused on abilties, even as lowering systemic toxicity and improving healing results [19]. Doxorubicin is used inside the treatment of an extensive range of cancers, such as breast most cancers, bladder cancer, Kaposi's sarcoma, lymphoma (Hodgkin's and non-Hodgkin's), acute lymphoblastic leukemia, and metastatic cancers (e.g., ovarian, gastric, thyroid, lung). at the same time as effective, doxorubicin is related to several side effects, inclusive of cardiotoxicity, bone marrow suppression, nausea, vomiting, hair loss, red urine discoloration, and hypersensitive reactions [20]. Cardiotoxicity is one of the most enormous side outcomes, main to congestive heart failure in some sufferers. Bone marrow suppression outcomes in decreased manufacturing of blood cells, main to anemia, leukopenia, and thrombocytopenia [21]. Nausea and vomiting are commonplace aspect outcomes controlled with antiemetics [22]. Hair loss is a common facet impact of many chemotherapy drugs. red urine discoloration is a harmless facet effect inflicting urine to show pink or red for a few days after management [23]. hypersensitive reactions, which includes anaphylaxis, occur in rare cases. Ongoing studies goals to improve doxorubicin therapy via mixture

treatments, nanoformulations, dose adjustment, and administration strategies [24]. Combining doxorubicin with different chemotherapy retailers or targeted remedies complements efficacy. Nanoformulations enhance focused on, reduce aspect results, and triumph over drug resistance. Dose adjustment and administration techniques optimize remedy results [25]. Doxorubicin remains a cornerstone in cancer chemotherapy because of its large-spectrum efficacy [26]. Advances in drug delivery structures and combination treatment plans maintain promise for reinforcing its therapeutic ability at the same time as minimizing negative effects [27]. Doxorubicin is available in various formulations to enhance its therapeutic efficacy and reduce facet results. some formulations are like that, loose shape which the conventional shape of doxorubicin administered intravenously [28]. Liposomal Formulations that Liposomal encapsulation improves drug transport to tumor tissues even as minimizing systemic toxicity. Examples include Doxil® (Caelyx®) and Myocet® [29]. Polymeric Micelles and Nanoparticles which those advanced formulations decorate drug solubility, balance, and concentrated on skills and Polymer-Drug Conjugated that those conjugates enhance drug delivery and reduce cardiotoxicity [30]. Tamer A eibayoumi, Vladimir P Torchilin, conducted clinical research, their effects illustrated, mAb 2C5–focused liposomes confirmed greater accumulation in tumors, and the in vivo healing interest of the mAb 2C5–Doxil treatment became determined to be substantially superior, resulting in final tumor weights of simplest 25% to 40% in comparison with all Doxil manipulate remedies, when examined against the s.c. primary murine tumors of 4T1 and C26 and human PC3 tumor in nude mice. They conclude that terrific functionality of 2C5-centered Doxil to in particular deliver its cargo into numerous tumors, significantly growing the efficacy of remedy [31].

Synergistic Effects of Paclitaxel and Doxorubicin

Some findings spotlight the capacity of mixing Paclitaxel and Doxorubicin in advanced drug transport systems to triumph over the restrictions of conventional chemotherapy and offer extra effective most cancers remedies [32]. The aggregate of Paclitaxel and Doxorubicin in nanoparticle formulations enhances their bioavailability and circulate time. This ensures that a higher concentration of the drugs reaches the tumor website, improving healing efficacy [33]. Combination of Paclitaxel and Doxorubicin well-knownshows potent anticancer interest towards numerous most cancers types. The synergistic effect of these capsules results in more suitable tumor regression and progressed affected person effects [34].

Paclitaxel's mitotic arrest and Doxorubicin's DNA damage synergistically promote cell demise.



Fig. 2. Chemical structure of doxorubicin

The mixture of Paclitaxel and Doxorubicin induces apoptosis more successfully than either drug on my own. Liposomal formulations of Paclitaxel and Doxorubicin enhance drug solubility, stability, and centered transport to tumor tissues, decreasing systemic toxicity [35].

Encapsulation in liposomes minimizes the delivery of these drugs to non-goal tissues, decreasing destructive effects consisting of cardiotoxicity related to Doxorubicin. Nanoparticle formulations improve the bioavailability and circulation time of Paclitaxel and Doxorubicin, ensuring a better concentration of the medicine reaches the tumor website [32].

Hesti Lina Wiraswati et al, discussed Drug interaction evaluation showed the combination become safe without a contraindications or side effects. moreover, molecular docking research revealed that doxorubicin-pyrazoline B and doxorubicin-cyclophosphamide may additionally synergistically inhibit most cancers mobile proliferation by means of inhibiting the binding of topoisomerase I to the DNA chain. moreover, the combination of pyrazoline B-paclitaxel can also has synergistic activity to cause apoptosis through inhibiting Bcl2 binding to the Bax fragment or inhibiting cell department by using inhibiting α-β tubulin disintegration. Paclitaxel-ascorbic acid had a synergistic impact at the inhibition of α-β tubulin disintegration. their results proven that this aggregate is promising for further in vitro and in vivo studies [36]. Tito N. Habib et al, tested Apoptosis Induction via the combination of Paclitaxel and Doxorubicin induces apoptosis greater correctly than both drug alone. that is done thru the modulation of apoptotic proteins inclusive of Bax and Bcl2, leading to elevated cell demise in most cancers cells. by mixture therapy with Paclitaxel and Doxorubicin has been shown to lessen the improvement of drug resistance compared to monotherapy. that is executed with the aid of concentrated on more than one pathways involved in cancer cell survival and proliferation, making it more difficult for cancer cells to expand resistance [37].

Jiaoyang Wang et al, stated unmarried-stranded DNA tail conjugated antitumor drug paclitaxel (PTX), and the co-delivery of PTX, doxorubicin and targeting agent mucin 1 (MUC-1) aptamer on a DNA nanobarrel provider. has investigated the effect of tail lengths on drug launch efficiencies and dual drug codelivery-enabled cytotoxicity. as a result of the unexpectedly growing discipline of structural DNA nanotechnology, practical DNA-primarily based drug shipping is promising to obtain clinical therapeutic applications [38].

LIPID NANOPARTICLES AS DRUG DELIVERY SYSTEMS

Characteristics of Lipid Nanoparticles

Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate both hydrophilic and lipophilic capsules. the mixing of Paclitaxel and Doxorubicin into liposomes includes encapsulating those pills inside the lipid bilayer or the aqueous middle of the liposome, depending on their solubility [39]. This encapsulation can be accomplished via numerous techniques, which include passive loading (wherein pills are included during liposome formation) and far flung loading (wherein pills are loaded into pre-formed liposomes the use of ion gradients) [40]. Lipid nanoparticles composed of lipids, typically ranging in length from 10 to 1000 nanometers. They own numerous key characteristics that lead them to appropriate for drug delivery [41] includ that, LNPs are made from a variety of lipids, including triglycerides, diglycerides, monoglycerides, fatty acids, steroids (e.g., ldl cholesterol), and waxes. those lipids may be blended to shape strong lipid nanoparticles (SLNs) or nanostructured lipid providers (NLCs) [42].

The core of SLNs consists of strong lipids, that could solubilize lipophilic (fats-soluble) molecules. This core is stabilized by using surfactants (emulsifiers) to prevent particle aggregation [43].

The floor of LNPs may be changed with targeting molecules consisting of antibodies, peptides, or other drug molecules to decorate their specificity and efficacy. Lipid nanoparticles are biodegradable and biocompatible, making them less probably to motive unfavorable reactions inside the body [44].

LNPs exhibit excessive physical and chemical balance, that's critical for retaining the integrity of the encapsulated drug in the course of storage and transport. LNPs have a high drug-loading capability, taking into consideration the incorporation of each hydrophilic (water-soluble) and lipophilic drugs [45]. LNPs may be used to supply an extensive range of therapeutic marketers, including small molecule capsules, proteins, peptides, and nucleic acids. These traits and benefits make lipid nanoparticles a valuable device in the improvement of extra effective and

safer most cancers healing procedures [46].

Integration of Paclitaxel and Doxorubicin with liposomes

Combining Paclitaxel and Doxorubicin with Liposome NP in most cancers therapy has proven promising synergistic effects, improving the efficacy and reducing the aspect outcomes of both pills. more desirable drug shipping and balance are executed thru liposomal formulations, which improve drug solubility, balance, and focused delivery to tumor tissues. This consequence in better healing effects. The ratiometric co-transport of those capsules the usage of far flung-loading liposomes guarantees a synergistic impact by means of retaining an most appropriate drug ratio [32]. Reduced systemic toxicity is some other widespread advantage of liposomal formulations of Paclitaxel and Doxorubicin. by encapsulating the medicine in liposomes, their shipping to non-goal tissues is minimized, lowering negative consequences. this is specifically important for Doxorubicin, which is understood for its cardiotoxicity. Liposomal encapsulation enables to mitigate this hazard, making the aggregate remedy more secure for patients [32]. Liposomes can triumph over biological barriers including the blood-mind barrier, improving the shipping of medication to difficult-to-attain tumors. This functionality is especially crucial for treating cancers which might be in any other case inaccessible to standard chemotherapy agents [47]. Nanoparticle formulations beautify the bioavailability and move time of Paclitaxel and Doxorubicin, ensuring a higher awareness of the medication reaches the tumor web page. This stepped forward bioavailability enhances the healing efficacy of the remedy [48]. Paclitaxel stabilizes microtubules, preventing their depolymerization and arresting the cell cycle on the G2/M phase, main to apoptosis. This disruption of microtubule dynamics arrests cancer cellular department [49]. Doxorubicin intercalates between DNA base pairs, disrupting DNA replication and transcription. It also inhibits topoisomerase II, main to DNA strand breaks and cellular loss of life. moreover, Doxorubicin induces the formation of reactive oxygen species (ROS), inflicting oxidative damage to mobile additives [50].

Fatemeh Ravar et al, hyaluronic acid focused liposomal formulation of paclitaxel became organized in which, hyaluronic acid become electrostatistically drawn to the surface of liposomes. Liposomes, had a particle size of 106.4 ± 3.2 nm, a weakly negative zeta potential of − nine.7 ± 0.8 mV and an appropriate encapsulation performance of 92.1 ± 1.7%. the discharge profile of liposomes in buffer showed that 95% of PTX turned into released at some stage in 40 h. Confocal laser scanning microscopy and glide cytometry analysis confirmed the more cellular internalization of coumarin-loaded liposomes compared to unfastened coumarin. MTT assay on 4T1 and T47D cells confirmed the more potent cytotoxic pastime of liposomes in contrast to loose paclitaxel. mobile cycle analysis confirmed that cells had been specifically blocked at G2/M phases after 48 h treatment with liposomes. In vivo real time imaging on 4T1 tumor-bearing mice discovered that the liposomal formulation especially collected in the tumor vicinity. Liposomes also had higher antitumor efficacy against Cremophor-based totally system [51].

Anthracyclines, specially traditional doxorubicin, are essential in breast most cancers treatment, however their blessings are limited through their therapeutic index. Liposomal formulations, like pegylated liposomal doxorubicin, were evolved to improve this index, imparting tumor-targeted efficacy with fewer toxicities, such as myelosuppression, alopecia, nausea, vomiting, and considerably decreased cardiac toxicity. Pegylated liposomal doxorubicin has been evaluated in over 20 clinical trials, showing similar efficacy to conventional doxorubicin in metastatic breast most cancers, each as an unmarried agent and in combination with other treatments like cyclophosphamide, paclitaxel, docetaxel, gemcitabine, vinorelbine, and hyperthermia. response quotes variety from 27% to 83%, with median survival of 7–20 months. moreover, small research indicate its ability in treating locally superior breast cancer [52]. Fabio Pastorino et al, evaluated the efficacy of targeted liposomal doxorubicin (TVT-DOX) in human tumor xenografts of neuroblastoma, ovarian cancer, and lung cancer. Mice were implanted with tumor cells and treated with TVT-DOX, loose doxorubicin, or untargeted liposomes (Caelyx). consequences confirmed that TVT-DOX drastically stepped forward survival quotes in comparison to controls, in particular in neuroblastoma fashions, with lengthy-time period survivors mentioned. The remedy caused reduced tumor cellular proliferation, blood vessel density,

and multiplied apoptosis as assessed with the aid of immunohistochemistry and chick embryo assays. The findings endorse that TVT-DOX can be a promising angiostatic method for adjuvant remedy in stable tumors [53].

CLINICAL REPORTS

The mixing of Paclitaxel and Doxorubicin with liposomes has shown extensive promise in scientific research. those liposomal formulations have demonstrated stepped forward therapeutic outcomes, decreased side consequences, and greater patient first-class of existence. Ongoing studies continues to explore optimized dosing schedules, advanced drug shipping structures, and mixture cures to in addition beautify the efficacy and safety of this treatment method [32].

Schwonzen,M et al, studied on twenty-one sufferers with metastatic breast most cancers had been dealt with with pegylated liposomal doxorubicin (20 mg/m2, day 1) and paclitaxel (one hundred mg/m2, days 1 and eight) for 6 cycles each 2 weeks. All patients had had relapse or progression on one to five previous chemotherapies. They found sufferers with entire and 8 sufferers with partial remissions (48% response price). 8 of the 10 responders had had preceding therapy with epirubicin, doxorubicin or mitoxantrone. The imply remission length changed into five months. disease progression due to brain metastasis took place in 5 instances. severe aspect outcomes (grade three WHO) had been alopecia (a hundred%), skin toxicity in 29%, neuropathy in 24% and mucositis in 13%. Leukopenia (grade four WHO) become discovered in 48%, but there has been no cardiac toxicity, no dying and no hospitalization. The mixture of weekly paclitaxel and liposomal doxorubicin each 2 weeks is noticeably powerful in previously handled sufferers. primarily based at the doses administered, is propose 15 mg/m2 liposomal doxorubicin every 2 weeks and 80 mg/m2 paclitaxel weekly [54].

DA Vorobiof et al, cheked thirty-4 patients with superior breast most cancers had been treated with a combination of paclitaxel 175mg/m2 and liposomal doxorubicin 30mg/m2, each 3 weeks. The combination chemotherapy turned into effective in 73% of the patients (ITT) (95% CI 55–86%) (7 whole and 18 partial responses). Grade three/4 toxicities were documented in a small variety of sufferers. two toxic deaths (6%) have been documented, one a hepatorenal failure and every other a febrile neutropenia. One affected person experienced pulmonary embolism however persisted on remedy after suitable remedy. The aggregate of paclitaxel and liposomal encapsulated doxorubicin induces an excessive and durable reaction rate with a slight toxicity profile [55].

Yarong Liu et al, mentioned a brand new strong method to load tablets with one of a kind hydrophilicities into a single cross-connected multilamellar liposomal vesicle (cMLV) to precisely control the drug ratio that reaches the tumor in vivo. the stability of cMLVs improves the loading performance and sustained release of doxorubicin (Dox) and paclitaxel (PTX), maximizing the mixed healing impact and minimizing the systemic toxicity. moreover, we display that the cMLV formula continues precise drug ratios in vivo for over 24 h, enabling the ratio-structured aggregate synergy visible in vitro to translate to in vivo antitumor hobby and giving us manage over another parameter essential to mixture therapy. This combinatorial shipping device can also offer a new approach for synergistic shipping of multiple chemotherapeutics with a ratiometric manage over encapsulated capsules to deal with cancer and other sicknesses [48].

Xiangjun Chen et al, designed and fabricated fairly effective pH-responsive and biodegradable calcium orthophosphate@liposomes (CaP@Lip) NPs with a diameter of a hundred and ten ± 20 nm CaP@Lip NPs loaded with hydrophobic paclitaxel and hydrophilic doxorubicin hydrochloride accomplished exquisite drug loading efficiencies of 70 and 90%, respectively. under physiological conditions, the received NPs are negatively charged. however, they switched to definitely charged when uncovered to vulnerable acidic environments by way of which internalization can be promoted. furthermore, the CaP@Lip NPs exhibit an apparent structural disintegrate beneath acid conditions (pH 5.5), which confirms their incredible biodegradability. The “proton enlargement” effect in endosomes and the pH-responsiveness of the NPs facilitate the release of encapsulated pills from man or woman channels. The effectiveness and safety of the drug delivery structures were tested via in vitro and in vivo experiments, with a 76% inhibition of tumor boom. these findings highlight the high focused on capability of the drug-loaded NPs to tumor web sites thru the EPR effect, efficaciously suppressing

tumor growth and metastasis. by means of combining CaP NPs and liposomes, this examine now not handiest resolves the toxicity of CaP but also enhances the stableness of liposomes [56].

Isaac Izcoatl Mota Díaz et al, confirmed Biopolymer-coated liposomes had been evaluated for paclitaxel and doxorubicin co-encapsulation in MCF-7 and MDA-MB-231 breast most cancers cellines. those nanosystems are characterised through dynamic light scattering, transmission electron microscopy, and UV-VIS spectroscopy. The traditional and hybrid liposomal systems provided sizes of 150 to 230 nm and %EE greater than eighty% for the encapsulated active elements. those drug-weighted down liposomal structures extensively decreased cell viability in each breast cancer cellular traces as compared with liposome-free drugs [49]. Yingli Wang et al, pronounced a ratiometrically designed liposomal nanoplatform with synergistic efficacy, utilising remote loading to co-encapsulate ROS-touchy paclitaxel prodrug (PSN) and doxorubicin (DOX). This novel dual-transport liposome owns excessive two-drug encapsulation efficacy and colloidal balance, ensuing in synergistic cytotoxicity, extended blood stream, favorable biodistribution, continually keep the ratiometrically synergistic drug ratio in vivo, and powerful synergistic anticancer activity. this sort of aggregate of PSN and DOX with synergistic consequences encapsulated in a secure and powerful dual-shipping liposomal nanomedicine [32].

Zeljko Vujaskovic et al, studied concerned 43 sufferers with stage IIB-III regionally superior breast most cancers (LABC). They received neoadjuvant therapy with liposomal doxorubicin (30–75 mg/m²), paclitaxel (100–175 mg/m²), and hyperthermia. Following remedy, they underwent either changed radical mastectomy or lumpectomy with axillary node dissection, accompanied by means of radiation therapy and eight cycles of CMF chemotherapy. outcomes confirmed a blended medical response fee of 72% and a combined pathological reaction fee of 60%. 4 patients done a pathologically entire response, and 16 had been eligible for breast-holding surgical operation. The cumulative equivalent minutes (CEM 43) at T90 was considerably better for people with a pathological reaction. 4-12 months' disorder-unfastened survival was 63%, and the 4-12 months' ordinary survival changed into 75%. They finish that the neoadjuvant remedy routine combining paclitaxel, liposomal doxorubicin, and hyperthermia is possible and nicely-tolerated for LABC sufferers, with CEM 43 T90 being a considerable predictor of pathological reaction [57].

CONCLUSION

Combining Paclitaxel and Doxorubicin with lipid nanoparticles gives a transformative technique in cancer remedy, overcoming enormous limitations along with drug resistance, restricted bioavailability, and excessive aspect consequences. This synergistic mixture enhances drug delivery, stability, and focused motion against most cancers cells, main to improved healing efficacy and reduced systemic toxicity. The assessment of recent research highlights the enormous benefits of this novel components in imparting extra powerful and less poisonous cancer remedies. The destiny of cancer remedy with Paclitaxel and Doxorubicin lipid nanoparticles seems promising, with numerous areas warranting further investigation. persisted studies are critical to optimize the system and dosing regimens for max therapeutic benefit. The improvement of advanced liposomal transport structures incorporating targeting ligands and stimuli-responsive elements may want to similarly decorate specificity and efficacy. additionally, exploring the ability of mixing those nanodrugs with other remedy modalities, inclusive of immunotherapy and radiotherapy, may want to result in synergistic consequences and advanced patient results. long-time period clinical research is necessary to completely understand the safety and efficacy of these formulations, in the end paving the way for their massive adoption in clinical exercise. by way of addressing these demanding situations, the integration of Paclitaxel and Doxorubicin with lipid nanoparticles holds the capability to revolutionize most cancers treatment and appreciably improve affected person survival and nice of life.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this manuscript.

REFERENCES

1. Emens LA, Romero PJ, Anderson AC, Bruno TC, Capitini CM, Collyar D, et al. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer

(SITC) strategic vision. Journal for immunotherapy of cancer. 2024;12(6):e009063.
2. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009;69(9):3918-3926.
3. Krishna G, Thrimothi D. Nano Emulsions: A Novel Targeted Delivery of Cancer Therapeutics. Design and Applications of Self-Assembly Aggregates - From Micelles to Nanoemulsions: IntechOpen; 2024.
4. Rui M, Xin Y, Li R, Ge Y, Feng C, Xu X. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin. Mol Pharm. 2016;14(1):107-123.
5. Alavi M, Nokhodchi A. Micro- and nanoformulations of paclitaxel based on micelles, liposomes, cubosomes, and lipid nanoparticles: Recent advances and challenges. Drug Discovery Today. 2022;27(2):576-584.
6. Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resistance Updates. 2020;53:100715.
7. Gurunathan S, Kang M-H, Qasim M, Kim J-H. Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer. Int J Mol Sci. 2018;19(10):3264.
8. Favoni RE, Florio T. Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma. Trends Pharmacol Sci. 2011;32(8):463-479.
9. Borys F, Joachimiak E, Krawczyk H, Fabczak H. Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells. Molecules (Basel, Switzerland). 2020;25(16):3705.
10. Skubitz K. Paclitaxel. Encyclopedia of Cancer: Springer Berlin Heidelberg; 2014. p. 3368-3371.
11. Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, et al. Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy. Oxid Med Cell Longev. 2021;2021:3687700-3687700.
12. Lu H, Zha S, Zhang W, Wang Q, Jiang D, Xu X, et al. A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer. BMC Cancer. 2021;21(1):830-830.
13. Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA. Paclitaxel: What has been done and the challenges remain ahead. Int J Pharm. 2017;526(1-2):474-495.
14. A P, Kar S, Vignesh K, Kolhe UD. An Overview of Paclitaxel Delivery Systems. Sustainable Agriculture Reviews: Springer International Publishing; 2020. p. 161-215.
15. Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo H. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol. 2006;58(5):665-672.
16. Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin L, et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer. 2006;119(1):41-48.
17. Dicks LMT, Vermeulen W. Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play? Microorganisms. 2022;10(9):1733.
18. Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021;278:119527.
19. Boršev I, Mrđanovic J, Petrovic D, Seke M, Jović D, Srđenović B, et al. Nanoformulations of doxorubicin: how far have we come and where do we go from here? Nanotechnology. 2018;29(33):332002.
20. Masood I, Kiani MH, Ahmad M, Masood MI, Sadaquat H. Major Contributions towards Finding a Cure for Cancer through Chemotherapy: A Historical Review. Tumori Journal. 2015;102(1):6-17.
21. Găman AM, Egbuna C, Găman M-A. Natural bioactive lead compounds effective against haematological malignancies. Phytochemicals as Lead Compounds for New Drug Discovery: Elsevier; 2020. p. 95-115.
22. Shih V, Wan HS, Chan A. Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide. Ann Pharmacother. 2009;43(3):444-452.
23. Kamińska K, Cudnoch-Jędrzejewska A. A Review on the Neurotoxic Effects of Doxorubicin. Neurotox Res. 2023;41(5):383-397.
24. Galateanu B, Pușcașu AI, Tircol SA, Tanase BC, Hudita A, Negrei C, et al. Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions. Int J Mol Sci. 2023;24(4):3886.
25. Mir SA, Hamid L, Bader GN, Shoaib A, Rahamathulla M, Alshahrani MY, et al. Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review. Molecules (Basel, Switzerland). 2022;27(19):6608.
26. Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood. 2018;132(3):245-253.
27. Alharbi HM. Exploring the Frontier of Biopolymer-Assisted Drug Delivery: Advancements, Clinical Applications, and Future Perspectives in Cancer Nanomedicine. Drug Des Devel Ther. 2024;18:2063-2087.
28. Jiang W, Lionberger R, Yu LX. In Vitro and In Vivo Characterizations of Pegylated Liposomal Doxorubicin. Bioanalysis. 2011;3(3):333-344.
29. Shapiro CL. Liposome-encapsulated doxorubicin is less cardiotoxic than conventional doxorubicin for metastatic breast cancer. Evidence-based Oncology. 2002;3(3):110-112.
30. O. Abioye A, Tangyie Chi G, T. Kola-Mustapha A, Ruparelia K, Beresford K, Arroo R. Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs. Pharmaceutical Nanotechnology. 2016;4(1):38-79.
31. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(6):1973-1980.
32. Wang Y, Chen L, Zhang Z, Liu W, Li L. Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer. Drug Delivery and Translational Research. 2022;12(10):2537-2549.
33. Sarkar M, Wang Y, Ekpenyong O, Liang D, Xie H. Pharmacokinetic behaviors of soft nanoparticulate

formulations of chemotherapeutics. Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology. 2023;15(2):e1846-e1846.
34. Qin S-Y, Cheng Y-J, Lei Q, Zhang A-Q, Zhang X-Z. Combinational strategy for high-performance cancer chemotherapy. Biomaterials. 2018;171:178-197.
35. BR96-Doxorubicin Immunoconjugate. Definitions: Qeios; 2020.
36. Wiraswati HL, Bashari MH, Alfarafisa NM, Ma'ruf IF, Sholikhah EN, Wahyuningsih TD, et al. Pyrazoline B-Paclitaxel or Doxorubicin Combination Drugs Show Synergistic Activity Against Cancer Cells: In silico Study. Advances and applications in bioinformatics and chemistry : AABC. 2024;17:33-46.
37. Habib TN, Altonsy MO, Ghanem SA, Salama MS, Hosny MA. Optimizing combination therapy in prostate cancer: mechanistic insights into the synergistic effects of Paclitaxel and Sulforaphane-induced apoptosis. BMC molecular and cell biology. 2024;25(1):5-5.
38. Wang J, Zhang T, Li X, Wu W, Xu H, Xu Xm, et al. DNA Nanobarrel-Based Drug Delivery for Paclitaxel and Doxorubicin. ChemBioChem. 2023;24(19).
39. Kraft JC, Freeling JP, Wang Z, Ho RJY. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci. 2014;103(1):29-52.
40. Pisani S, Di Martino D, Cerri S, Genta I, Dorati R, Bertino G, et al. Investigation and Comparison of Active and Passive Encapsulation Methods for Loading Proteins into Liposomes. Int J Mol Sci. 2023;24(17):13542.
41. Mudshinge SR, Deore AB, Patil S, Bhalgat CM. Nanoparticles: Emerging carriers for drug delivery. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. 2011;19(3):129-141.
42. Markovic M, Ben-Shabat S, Aponick A, Zimmermann EM, Dahan A. Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics. Int J Mol Sci. 2020;21(9):3248.
43. Scioli Montoto S, Muraca G, Ruiz ME. Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects. Frontiers in molecular biosciences. 2020;7:587997-587997.
44. Patel D, Solanki J, Kher MM, Azagury A. A Review: Surface Engineering of Lipid-Based Drug Delivery Systems. Small. 2024;20(43).
45. Abdel-Mageed HM, Abd El Aziz AE, Mohamed SA, AbuelEzz NZ. The tiny big world of solid lipid nanoparticles and nanostructured lipid carriers: an updated review. Journal of Microencapsulation. 2022;39(1):72-94.
46. Kenchegowda M, Rahamathulla M, Hani U, Begum MY, Guruswamy S, Osmani RAM, et al. Smart Nanocarriers as an Emerging Platform for Cancer Therapy: A Review. Molecules (Basel, Switzerland). 2021;27(1):146.
47. Awais M, Batool S, Khan M, Asim L, Riaz R, Zafar R. Strategies for Crossing Biological Barriers in Drug Delivery. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences. 2023;94(2):235-243.
48. Liu Y, Fang J, Kim Y-J, Wong MK, Wang P. Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm. 2014;11(5):1651-1661.
49. Mota Díaz II, Douda J, García López P, Cabrera Becerra SE, Gómez Álvarez MÁ, Jiménez Rodríguez R, et al. Co-Encapsulation of Paclitaxel and Doxorubicin in Liposomes Layer by Layer. Colloids and Interfaces. 2024;8(4):42.
50. Singh I, Kumar S. Liposomes as Efficient Drug Delivery Vehicles to Combat Antimicrobial Resistance. Nanotechnology Based Strategies for Combating Antimicrobial Resistance: Springer Nature Singapore; 2024. p. 335-350.
51. Ravar F, Saadat E, Gholami M, Dehghankelishadi P, Mahdavi M, Azami S, et al. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation. Journal of Controlled Release. 2016;229:10-22.
52. O'Shaughnessy JA. Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer. Clin Breast Cancer. 2003;4(5):318-328.
53. Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, et al. Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin. Clinical Cancer Research. 2008;14(22):7320-7329.
54. Schwonzen M, Kurbacher CM, Mallmann P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anti-Cancer Drugs. 2000;11(9):681-685.
55. Vorobiof DA, Rapoport BL, Chasen MR, Slabber C, McMichael G, Eek R, et al. First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer: a multicentre phase II study. The Breast. 2004;13(3):219-226.
56. Chen X, He H, Guo X, Hou M, Zhang X, Li S, et al. Calcium Orthophosphate in Liposomes for Co-Delivery of Doxorubicin Hydrochloride/Paclitaxel in Breast Cancer. Mol Pharm. 2023;20(8):3914-3924.
57. Vujaskovic Z, Kim DW, Jones E, Lan L, McCall L, Dewhirst MW, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2010;26(5):514-521.